Founder and CEO Albert Buyske, PhD, died Dec. 8 at the age of 64. Prior to founding Somerset, he held executive and scientific positions at Lederle, Ayerst Labs Canada, Warner Lambert, Johnson & Johnson and S.C. Johnson.Buyske was responsible for Somerset's licensing of the anti-Parkinson's drug Eldepryl from the Hungarian government. Somerest was later acquired by generic firms Bolar and Mylan in a joint venture.
You may also be interested in...
The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.
Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.